Résumé et objectifs du CARPEM

Carpem > Présentation > Présentation générale > Résumé et objectifs du CARPEM

CARPEM CAncer Research for PErsonalized Medicine


Two Paris-based hospitals, HEGP and Cochin/Hôtel-Dieu, both linked to Paris Descartes University, are applying together for the SIRIC grant. Our integrative research program called CARPEM (for CAncer Research and PErsonalized Medicine) will associate more than 250 researchers and 100 hospital-based, cancer-dedicated physicians. Twenty-two research teams will take part in the SIRIC call for proposal. They have outstanding academic assessment.

The CARPEM program will be coordinated by Pr. P. Laurent-Puig and Pr. WH Fridman.


translational research


The CARPEM program is based on a better understanding of the mechanisms of carcinogenesis and the relationship between tumor and host microenvironment, in order to translate this knowledge into an improved cancer patient management.

Our program will integrate knowledge coming from the analysis of tumor genomics, interactions between tumor and its microenvironment and host genetic variations to develop new prognostic and theranostic biomarkers as well as innovative therapeutics. CARPEM will focus on selected tumour types (digestive, lung, head and neck, renal, endocrine, hematological).

8 tumors types


The CARPEM program will develop the following crossdisciplinary research objectives leading to the development of personalized medicine:

– Identification of genetic and immunology based prognostic and predictive biomarkers with the help of translational project and epidemiological cohorts

– Development of experimental therapeutics

– Integration of Ethics and assessment of practices in the CARPEM research program.




These objectives will be reached thanks to 3 research programs described hereafter.

• The translational research project “from genes to personalized medicine” aims to solve core problems related to the treatment of selected solid and hematological tumors, for which CARPEM teams have recently shown their innovative skills. Our strategy starts from basic research projects developed using a wide-range of genomic, cellular and animal approaches to identify new genetic or epigenetic drivers that would be critical for a more personalized therapeutic approach. Findings obtained from human tissue samples applying high throughput technologies will be confirmed in experimental models and translated into biomarkers and targets for high impact clinical use.

• The translational research project “from cell to personalized medicine” aims to establish a bridge between comprehensive analysis of tumor microenvironment and the identification of relevant biomarkers predicting the clinical outcome of patients and/or the response to various cancer therapies. In addition, the development of innovative therapeutics will benefit from a better knowledge of the tumor microenvironment but also of the availability of original preclinical models and novel immunomodulators.

Epidemiology will constitute a common aspect of these programs particularly for the validation of potential biomarkers

• The third research project will integrate ethical and psychosocial aspect of cancer as complementary to the above programs of research. The patient/ caregiver relationship, and more specifically, how the concept of personalized medicine is understood by the patient is also an important parameter. For better interaction an ethical and assessment of practices committee and patients committee will be created.



Joining forces on the cancer research front shall make the Paris Descartes cancer research strategy a model for academic excellence in integrative cancer research.